Radiology Communities
Modalities
Specialties
Software Type
Featured Products
News Headlines
Main Headlines
- Six-month follow-up diagnostic mammograms recommended for women with probably benign lesions
- Incidental findings on cardiac multidetector row CT common for healthy adults
- Committee evaluates impact of planned cut to Medicare physician fee payments
- Siemens introduces new versatile laptop ultrasound system
- Ultrasound first, not CT, for diagnosing suspected acute appendicitis
Breast Imaging Radiology
- Six-month follow-up diagnostic mammograms recommended for women with probably benign lesions
- Five percent of breast tumors may double in month
- Breast cancer tumors grow faster in younger women
- Women in Brussels provided choice of mammography with unmatched lowest radiation dose
- Community breast center experience shows real-world application of breast-specific gamma imaging has significant impact on clinical care
Abdominal-Pelvic Radiology
- Ultrasound first, not CT, for diagnosing suspected acute appendicitis
- Dutch authorize manufacture of Vaccinogen's new cancer vaccine; license clears path to European production, final FDA trial
- Premalignant gastric lesions need routine surveillance: Dutch study
- Diagnostic imaging radiation 'must be minimized' in Crohn's disease, researchers say
- EGFR gene variants have gender-specific effects on colon cancer survival
Cardiac Radiology
- Acute AF causes local cardiac platelet activation within minutes
- Workouts sculpt heart as well as muscles
- Osteoporosis, osteopenia linked with coronary artery disease
- Volcano announces participation in SATURN clinical trial sponsored by AstraZeneca
- XTENT announces clinical trial data to be presented at annual EuroPCR meeting next week
Thoracic Radiology
- Ultrasound useful in detecting chest wall invasion by lung tumor
- Fluoroscopy not reliable for detecting causes of stridor in children
- Minimally invasive endograft offers superior results
- Researchers light up lungs to help diagnose disease
- Lung ultrasound to become "new visual stethoscope" in dyspnea
Musculoskeletal Radiology
- Osteoporosis, osteopenia linked with coronary artery disease
- Osteoporosis screening guidelines for men issued
- Abatacept shows ongoing benefit in arthritis patients
- Diabetes drugs may be related to fracture risk
- Epilepsy drug causes bone loss in young women
Neuro Radiology
Question of the Week
Is PET ready to take the place as the new gold standard method for the characterization of solitary pulmonary nodules?
Speakers' Corner
Submit your articles for publication on the Medicexchange Speakers' Corner.
Submit Now!
Submit Now!
Recent Speakers' Corner Articles
| Current location: | Home / Radiology News |
Volcano announces participation in SATURN clinical trial sponsored by AstraZeneca
Source: Volcano Corporation
Author:
Date: Tue, 6 May 2008
Author:
Date: Tue, 6 May 2008
Volcano Corporation (NASDAQ:VOLC) , a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today participation in SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN). This marks the first major pharmaceutical trial allowing physicians to use the Volcano Revolution (R) 45 MHz IVUS Imaging catheter as part of the protocol.
SATURN is a 104-week, parallel-group, multicentre, double-blind, Phase IIIb intravascular ultrasound (IVUS) imaging study of approximately 1,300 patients at 170 centres worldwide. This study by AstraZeneca is designed to measure the impact of CRESTOR (TM) (rosuvastatin) 40 mg and atorvastatin (Lipitor(R)) 80 mg on the progression of atherosclerosis in high risk patients. SATURN will compare the effects of these two statins on the ability to decrease progression or induce regression of atherosclerosis, the main cause of cardiovascular disease, following two years of treatment in patients with coronary artery disease.
The SATURN study is chaired by Steve Nissen, MD, with Steve Nichols, MD from the Cleveland Clinic Core Lab as the principle investigator. Under this protocol, physicians enrolling patients may select the Volcano Revolution(R) IVUS catheters as their IVUS catheter of choice.
SATURN is a 104-week, parallel-group, multicentre, double-blind, Phase IIIb intravascular ultrasound (IVUS) imaging study of approximately 1,300 patients at 170 centres worldwide. This study by AstraZeneca is designed to measure the impact of CRESTOR (TM) (rosuvastatin) 40 mg and atorvastatin (Lipitor(R)) 80 mg on the progression of atherosclerosis in high risk patients. SATURN will compare the effects of these two statins on the ability to decrease progression or induce regression of atherosclerosis, the main cause of cardiovascular disease, following two years of treatment in patients with coronary artery disease.
The SATURN study is chaired by Steve Nissen, MD, with Steve Nichols, MD from the Cleveland Clinic Core Lab as the principle investigator. Under this protocol, physicians enrolling patients may select the Volcano Revolution(R) IVUS catheters as their IVUS catheter of choice.
